ABSTRACT
INTRODUCTION
Childhood asthma is a highly prevalent chronic disease and its exacerbation is one of the most distressing events. 1, 2 Recognition of patients at high risk for asthma exacerbations is thus important for future asthma care and outcome. Current asthma treatment guidelines have increasingly focused on how to best assess asthma control because poor asthma control can lead to severe asthma exacerbations. 3 Fractional exhaled nitric oxide (FeNO) has been suggested as an effective risk marker of deterioration in asthma control. 4 In addition, there are several studies reporting the usefulness of FeNO measurements in prediction of upcoming asthma impairment among asthmatic individuals. [5] [6] [7] Because of fluctuations and inconsistency of FeNO which are related to multiple confounding factors, 8, 9 single FeNO measurement may not be predictive of future asthma exacerbations. Therefore, repeated FeNO measurements for a certain period of time may be needed to obtain more clarified information about the ongoing status of asthma.
SUMMARY AT A GLANCE
High bronchodilator response (BDR) as well as high fractional exhaled nitric oxide (FeNO) are associated with increased risk of asthma control losses among children with atopic asthma. Combined use of BDR and FeNO measurements could improve the prediction capacity for upcoming asthma control losses.
Because there is a substantial within-subject variability of bronchodilator responses (BDRs), 10, 11 repetitive measurements over time are sometimes required to make decisions on whether patients have significant BDRs. Clinical and prognostic significance of a positive BDR among asthmatic patients remains elusive because previous studies examining relations between BDRs and other asthma outcomes have shown mixed results. [12] [13] [14] [15] In this study, we investigated whether combination of FeNO and BDR measurements improves the prediction capacity of upcoming asthma control losses in children with atopic asthma.
METHODS

Subjects
Asthmatic patients aged 8-16 years were recruited from the outpatient clinic of the Chungbuk National University Hospital, Cheongju, Republic of Korea. To qualify, subjects were required to have atopy demonstrated by the ImmunoCAP system (Immunodiagnostics; Thermo Fisher Scientific, Uppsala, Sweden) and diagnoses of asthma based on the documentation of airway hyperresponsiveness (concentration of methacholine causing a 20% fall in forced expiratory volume in the 1 s (FEV 1 ) (PC 20 ) ≤ 8 mg/mL) and/or reversible airflow obstruction (a 12% or greater change in FEV 1 in response to inhaled short-acting β 2 -agonist). All enrolled patients were classified as having intermittent or mild persistent asthma based on the guidelines from the National Asthma Education and Prevention Program. 16 The study was approved by the Ethics Committee of Chungbuk National University Hospital Institutional Review Board and all parents of children signed a written informed consent.
Study design
The study protocol, separated into monitoring and observation periods, was conducted between March 2010 and February, 2015. During the monitoring period, each patient visited the clinic every 2-3 months (sometimes every 1 month) and received BDR and FeNO measurements. Thus, it took about 2 years to complete 10 measurements. In case of patients who developed worsening of asthmatic symptoms, it took more than 2 years because inhaled corticosteroid (ICS) treatments decreased the chances of receiving BDR and FeNO measurements without the influence of medications. Participants who had uncontrolled asthma received treatment with 200-400 μg of budesonide bd for at least 3 months and were taken off ICS treatments when asthma control was maintained for at least 1 month. Individuals whose asthma remained uncontrolled requiring dose escalation or systemic corticosteroids were excluded from the study. During a 1-year observation period, participants were asked to complete follow-up assessments every 2 months for a total of six visits. Participants were encouraged to be seen by the investigators in the outpatient clinic or emergency department if their asthma was uncontrolled. Children were asked to bring symptom diaries to the hospital and a loss of control was assessed at each clinic visit. After confirming that asthma control was maintained for more than 1 month without use of controller medications, each period was commenced. According to the previous report, 17 patients were classified as having controlled asthma if their Asthma Control Questionnaire 5 (ACQ5) scores were <0.75. In contrast, asthma control losses were defined if ACQ5 scores were 1.5 or higher.
FeNO measurements
FeNO measurements were performed using an NO analyser with electrochemical sensors (NIOX MINO; Aerocrine AB, Solna, Sweden), according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines 18 and expressed as parts per billion (ppb). After inhalation of NO-free air through a mouthpiece to total lung capacity, subjects then exhaled at a constant flow rate of 50 mL/s. Exhalation times were 10 s with a 2-min analysis period. FeNO was measured twice and a third measurement was performed if there was more than 10% difference between the first two measurements.
Pulmonary function testing
Lung function tests were performed with a spirometer (Vmax, SensorMedics, Yorba Linda, CA, USA) in accordance with ATS/ERS recommendations. 19 Percent predicted values were calculated based on Third National Health and Nutrition Examination Survey. 20 Methacholine PC 20 and BDRs to salbutamol (400 μg) were measured according to ATS/ERS guidelines. 
Statistical analysis
Total serum IgE, methacholine PC 20 , blood eosinophil count and FeNO values were logarithmically transformed to assume a normal distribution. The interreadings variability for FeNO and BDR was estimated by intraclass correlation (ICC) analysis. The correlation between BDR and FeNO was evaluated using the Pearson correlation coefficient. Student's t-test and chi-square test were used to compare demographic or clinical variables between groups with positive and negative BDR (≥12% vs <12%) or between groups with high and low maximal value of FeNO (M-FeNO) (>35 ppb vs ≤35 ppb). Kaplan-Meier estimates for the proportion of patients who maintained asthma control were used to describe occurrence of losses of asthma control over time. 
RESULTS
Patient characteristics
We initially enrolled 253 children with atopic asthma. Of these subjects, 218 children could be monitored over 2 years with BDR and FeNO measurements more than 10 times when they were not receiving controller medications. Of the 218 children, 192 finished six follow-up visits during the 1-year observation period. Nine children who were lost to follow-up were included in the analyses because these patients already had uncontrolled asthma before follow-up losses. Therefore, the full analysis set included a total of 201 subjects. Of these, 74 subjects were also included in our previous study, 7 while 127 new subjects were enrolled specifically for this study. Demographic information for these patients at the beginning of the observation period is summarized in Table 1 . The ACQ5 score at the beginning of the observation period was 0.45 AE 0.18 (mean AE SD).
Comparison between patients with high and low M-BDR
During the monitoring period, 119 (59%) subjects had one or more positive BDR, while 82 (41%) subjects did not show any positive BDR (Table 2) . Study patients were dichotomized into positive and negative BDR groups based on M-BDRs (≥12% for BDR pos vs <12% for BDR neg ). The mean M-BDRs of the BDR pos and BDR neg groups were 20.5% (95% CI: 18.9-22.1) and 7.9% (95% CI: 7.5-8.4). The lowest values of %FEV 1 , FEV 1 /forced vital capacity (FVC) and percent predicted forced expiratory flow between 25% and 75% of vital capacity (%FEF ) (L-%FEV 1 , L-FEV 1 /FVC and L-%FEF , respectively) were significantly lower in the BDR pos group than those in the BDR neg group.
Comparison between patients with high and low M-FeNO
As shown in Table 3 , M-FeNO higher than 35 ppb was found in 155 (77%) subjects throughout the course of the monitoring period, while M-FeNO in 46 (33%) subjects was 35 ppb or lower. Study participants were also dichotomized into groups of high and low FeNO on the basis of M-FeNO (>35 ppb for FeNO high vs ≤35 ppb for FeNO low ). The geometric mean M-FeNO in the FeNOhigh group was 65.8 ppb (95% CI: 61.7-69.8 ppb) which was significantly higher than 27.1 ppb (95% CI: 25.5-28.6 ppb) in the FeNO low group.
Inter-reading variability of BDR and FeNO
When we assessed the inter-reading variability for 
Association between BDR and FeNO
To observe the association between airway reversibility and inflammation, we estimated the correlation between BDR and FeNO in our study participants which were measured simultaneously when patients were not receiving controller medications for more than 1 month before evaluations. As shown in Figure 1 , there was no correlation between these two variables (r = −0.105; P = 0.137). To investigate whether BDR and FeNO measurements in combination provides prognostic information , forced expiratory flow between 25% and 75% of vital capacity; FeNO, fractional exhaled nitric oxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; L-%FEF , lowest value of percent predicted FEF The proportion of patients in four groups who had their first asthma control losses was estimated over time by using the Kaplan-Meier method (Fig. 2) 
Risk of asthma control losses based on BDR and FeNO
DISCUSSION
In this study, we investigated whether the combination of BDR and FeNO measurements could improve the prediction capacity of upcoming asthma control losses in atopic asthmatic children. We determined the maximal values of BDR and FeNO after repeated measurements because these two parameters were prone to fluctuation. In addition, we reduced the effect of ICS or other controller medications on BDR and FeNO as much as possible to find out true status of airway reversibility and inflammation. We dichotomized study participants into two groups of high and low BDR with a cut-off M-BDR value of a 12% increase in FEV 1 . Although validity of a 12% cutoff value has been questioned in the paediatric population, 13, 22 this cut-off value has been generally applied to inclusion of subjects in several childhood asthma trials. 23, 24 We also dichotomized patients into two groups of high or low FeNO using a cut-off M-FeNO value of 35 ppb which was suggested as a possible indicator of significant airway eosinophilia in children by ATS guidelines. 25 These BDR and FeNO cut-off values were thought to be adequate for dichotomization because they provided a better assessment of risks when compared with other cut-off values in this study.
There was no relationship between FeNO and BDR which were measured simultaneously. This finding may be explained by the fact that while FeNO is simply dependent on ongoing airway inflammation, BDRs are influenced by short-and long-term effects of airway inflammation. A short-term effect of airway inflammation on the elevation of BDR has been demonstrated in a study of serial bronchial biopsy specimens before and after ICS therapy in asthmatic individuals. 26 On the other hand, BDR is also influenced by airway remodelling which may be a consequence of long-term airway inflammation from an early age. 27, 28 In addition, the degree of BDRs was impaired in a subgroup of asthmatic patients with airway remodelling markers. 29 Therefore, BDR may vary considerably according to the level of airway remodelling among asthmatic patients and not always reflect ongoing airway inflammation.
Inter-reading (intraindividual) variability of BDR and FeNO was found to be high because ICC coefficients of <0.5 represent poor reliability. 30 Thus, the predictive values of a single measurement of these markers may not be sufficiently sensitive or specific to justify use of FeNO or BDR as a predictor of asthma control. In fact, we observed that a single measurement of these markers was not effective for predicting asthma control losses in Cox proportional hazards model (data not shown). To overcome this challenge, we selected maximal values after longitudinal measurements and used these values for analysis. Using this approach, we could show that BDR combined with FeNO improve the prediction capability of upcoming losses of control. Furthermore, lack of relationship between BDR and FeNO strongly suggests the necessity of combination of BDR and FeNO measurements to improve the accuracy in predicting future losses of control.
In our previous study, 7 despite that subjects with asthma control losses had significantly higher M-BDR than those who maintained asthma control, M-BDR was not an independent predictor of upcoming asthma control losses in a multiple logistic regression analysis. We guess that this result might come from intercorrelation between M-BDR and other covariates such as FEV 1 which were included in multivariate analysis. For this reason, we did not include other covariates except age, sex, anthropometric data and exposure to cigarette smoke for analysis in this study.
There are limitations to this study. First, our study was limited to children with an ACQ <0.75, no ICS treatment and no exacerbation during the follow-up. Because patients with severe asthma were excluded from the study, our study could not cover the pattern of response in patients with more severe asthma. Second, we converted continuous variables into categorical variables to see whether measurements of BDR and FeNO in combination could be more predictive of future deteriorations of asthma control. Therefore, dichotomization by our necessity might lead to pooling groups with different risks and to an unrealistic step function for risk.
In summary, high BDRs as well as high FeNO were found to be associated with a significant increase in risk of control losses among patients with atopic asthma. Together with this finding, lack of relationship between BDR and FeNO supported the combined use of both parameters, which provided prognostic information superior to either method alone. 
